RxDoctor Payments Data

Roy Sauberman, MD

Clinical Cardiac Electrophysiology · Brick, NJNPI 1912948142

Payments from drug & device makers

$9,432in general payments, 2019–2025

Across 193 payments — averaging $48.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Abbott$2K
  • Biosense Webster, Inc.$929
  • Biotronik Inc.$419
  • Impulse Dynamics (USA) Inc.$289
  • plus $789 from 17 others

What the payments were for

  • Consulting fees$4505%
  • Travel & lodging$2,61728%
  • Food & beverage$6,36567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,432 in reported general payments places this provider in the 25th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$279,595
Medicare patients
811
Services billed
2,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$305,643
XareltoRivaroxaban41$51,298
MultaqDronedarone Hcl23$21,181
Amiodarone Hcl127$6,426
Propafenone Hcl ErPropafenone Hcl16$4,741
Flecainide Acetate50$2,529
Metoprolol Succinate143$1,946
Dofetilide25$1,573
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$423
Metoprolol Tartrate38$375
ClopidogrelClopidogrel Bisulfate21$338
SotalolSotalol Hcl22$285
Digoxin17$201
Cephalexin56$162
Amlodipine Besylate33$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$305,643259 claims
Johnson & JohnsonXarelto$76$51,29841 claims
Sanofi-aventis U.S. LLCMultaq$29$21,18123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →